- Home
- BAND vs PROK Comparison
BAND vs PROK Comparison
Compare BAND & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAND
- PROK
- Stock Information
- Founded
- BAND 2000
- PROK 2015
- Country
- BAND United States
- PROK United States
- Employees
- BAND N/A
- PROK N/A
- Industry
- BAND Computer Software: Prepackaged Software
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAND Technology
- PROK Health Care
- Exchange
- BAND Nasdaq
- PROK Nasdaq
- Market Cap
- BAND 473.2M
- PROK 417.1M
- IPO Year
- BAND 2017
- PROK N/A
- Fundamental
- Price
- BAND $14.46
- PROK $2.51
- Analyst Decision
- BAND Buy
- PROK Strong Buy
- Analyst Count
- BAND 6
- PROK 4
- Target Price
- BAND $20.80
- PROK $6.25
- AVG Volume (30 Days)
- BAND 220.7K
- PROK 1.6M
- Earning Date
- BAND 10-30-2025
- PROK 11-10-2025
- Dividend Yield
- BAND N/A
- PROK N/A
- EPS Growth
- BAND N/A
- PROK N/A
- EPS
- BAND N/A
- PROK N/A
- Revenue
- BAND $756,118,000.00
- PROK $744,000.00
- Revenue This Year
- BAND $2.76
- PROK $471.74
- Revenue Next Year
- BAND $14.34
- PROK N/A
- P/E Ratio
- BAND N/A
- PROK N/A
- Revenue Growth
- BAND 7.42
- PROK N/A
- 52 Week Low
- BAND $11.33
- PROK $0.46
- 52 Week High
- BAND $22.22
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- BAND 37.43
- PROK 37.90
- Support Level
- BAND $13.85
- PROK $2.56
- Resistance Level
- BAND $14.91
- PROK $2.88
- Average True Range (ATR)
- BAND 0.61
- PROK 0.24
- MACD
- BAND -0.15
- PROK -0.06
- Stochastic Oscillator
- BAND 17.75
- PROK 1.53
About BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.